ω-3 PUFAs can provide cancer preventive actions in patients with longstanding inflammatory bowel disease, using molecular mechanisms such as blocking β-catenin dissociation complex, inducing tumor suppressive 15-PGDH, inhibiting COX-2 and NF-κB, and inducing selective apoptosis in cancer cells. Here, HPGD is linked to inflammatory bowel disease.